- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00445198
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Edmonton, Canada, T6G 1Z2
- Site Reference ID/Investigator# 7493
-
Ottawa, Canada, K1H 8L6
- Site Reference ID/Investigator# 7635
-
-
-
-
-
Leicester, Regno Unito, LE1 5WW
- Site Reference ID/Investigator# 18541
-
Manchester, Regno Unito, M20 4BX
- Site Reference ID/Investigator# 2622
-
-
-
-
Arizona
-
Peoria, Arizona, Stati Uniti, 85381
- Site Reference ID/Investigator# 13605
-
Phoenix, Arizona, Stati Uniti, 85013
- Site Reference ID/Investigator# 5261
-
-
California
-
Los Angeles, California, Stati Uniti, 90095-7187
- Site Reference ID/Investigator# 11942
-
Sacramento, California, Stati Uniti, 95817
- Site Reference ID/Investigator# 4718
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045-0510
- Site Reference ID/Investigator# 3755
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Site Reference ID/Investigator# 8324
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Site Reference ID/Investigator# 2623
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21231-1000
- Site Reference ID/Investigator# 2625
-
Bethesda, Maryland, Stati Uniti, 20892
- Site Reference ID/Investigator# 12343
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Site Reference ID/Investigator# 11941
-
Boston, Massachusetts, Stati Uniti, 02215
- Site Reference ID/Investigator# 2626
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Site Reference ID/Investigator# 4934
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Site Reference ID/Investigator# 2624
-
-
Washington
-
Tacoma, Washington, Stati Uniti, 98405
- Site Reference ID/Investigator# 6650
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The subject must be >=18 years of age.(Phase 1 & 2a)
- Histologically and/or cytologically documented diagnosis of small cell lung cancer (North America & UK) or other non-hematological malignancy (North America only).(Phase 1 only)
- Histologically and/or cytologically documented diagnosis of SCLC.(Phase 2a)
- At least one prior chemotherapy treatment regimen(s) and their disease is refractory or experienced progressive disease following the treatment.(Phase 1)
- Extensive-stage SCLC & is chemotherapy naïve(US only) has experienced progressive disease following at least one chemotherapy regimen or their disease is refractory.(Phase 2a)
- Brain metastases with clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function & no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
- ECOG performance score <= 2(Ph 1) <=1(Phase 2a)
- Must be receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants 21 days prior to 1st dose of study drug.
Adequate bone marrow, renal & hepatic function per local lab reference range at Screening as follows:
- Bone marrow: Absolute Neutrophil count (ANC)>=1000/µL
- Platelets>= 100,000/mm3
- Hemoglobin>=9.0g/dL
- Renal function: Serum creatinine<= 2.0mg/dL or calculated creatinine clearance>=50mL/min
- Hepatic function&enzymes: AST and ALT<=3.0 x the upper normal limit(ULN) of institution's normal range
- Bilirubin<=1.5xULN. If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
- Coagulation: aPTT and PT<=1.2 x the upper limit of normal
- Should have archived diagnostic tissue available for assessment of Bcl-2 family protein expression.(Phase 2a)
- All female subjects not surgically sterile or postmenopausal(for at least 1 year)and non-vasectomized male subject must practice at least one method of birth control.
Exclusion Criteria:
- Underlying or predisposing condition of bleeding or currently exhibits signs of bleeding.
- Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.
- Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.
- The subject has active immune thrombocytopenic purpura (ITP),active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
- Currently receiving or requires anticoagulation therapy or any drug or herbal supplements that affect platelet function, with exception of low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter.
- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti estrogen analogs, agonists required to suppress serum testosterone levels), or any investigational therapy within 14 days prior to the first dose of study drug, or has not recovered to less than a grade 2 adverse effect(s) of the previous therapy.
- Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the first dose of study drug.
- Steroid therapy for anti-neoplastic intent within seven days prior to the first dose of study drug.
- Has consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.
- Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
- Positive for HIV
A history of other active malignancies within the past 3 years prior to screening, with the exception of:
- Adequately treated in situ carcinoma of the cervix uteri
- Basal or squamous cell carcinoma of the skin
- Previous malignancy confined and surgically resected with curative intent
Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- Active systemic fungal infection
- Diagnosis of fever and neutropenia within 1 week prior to study drug administration.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Phase 1 and Phase 2a
|
Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing. - 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study. Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing. - 40 patients with SCLC |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Safety assessment
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Dose limiting toxicity determination
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Maximum tolerated dose determination
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Pharmacokinetic profile evaluation
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Extended safety assessment at the recommended Phase 2 dose
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Preliminary efficacy assessment
Lasso di tempo: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- M06-822
- 2006-003298-28 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su ABT-263
-
Kathleen LudwigA disposizioneInfanzia recidiva TUTTI | Linfoma linfoblastico infantile recidivatoStati Uniti
-
AbbVieA disposizioneMielofibrosi | Linfoma linfoblastico | Leucemia linfocitica acuta (ALL)Stati Uniti
-
AbbVie (prior sponsor, Abbott)CompletatoLeucemia linfatica cronicaStati Uniti, Australia, Israele, Polonia, Ucraina
-
AbbottGenentech, Inc.CompletatoSoggetti femminili saniStati Uniti
-
National Cancer Institute (NCI)TerminatoNeoplasia solida maligna refrattaria | Neoplasia solida maligna ricorrente | Neoplasia solida maligna metastatica | Neoplasia solida non resecabile | Carcinoma polmonare ricorrente a piccole cellule | Carcinoma polmonare a piccole cellule in stadio IIIA AJCC v7 | Carcinoma polmonare a piccole cellule... e altre condizioniStati Uniti
-
AbbVieTerminatoMielofibrosi (MF)Stati Uniti, Corea, Repubblica di, Sud Africa
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamentoLeucemia mieloide acuta ricorrente | Leucemia mieloide acuta refrattariaStati Uniti
-
AbbottGenentech, Inc.CompletatoLeucemia linfatica cronica | Linfomi | LeucemieStati Uniti
-
AbbVieAttivo, non reclutanteMielofibrosi (MF)Stati Uniti, Australia, Austria, Belgio, Bulgaria, Canada, Croazia, Francia, Germania, Grecia, Israele, Italia, Giappone, Corea, Repubblica di, Olanda, Nuova Zelanda, Federazione Russa, Serbia, Sud Africa, Spagna, Svezia, Ta... e altro ancora
-
National Cancer Institute (NCI)Attivo, non reclutanteStadio IIIA Carcinoma polmonare non a piccole cellule AJCC v7 | Carcinoma polmonare avanzato non squamoso non a piccole cellule | Carcinoma polmonare metastatico non squamoso non a piccole cellule | Stadio IIIB Carcinoma polmonare non a piccole cellule AJCC v7 | Stadio IV Carcinoma polmonare... e altre condizioniStati Uniti